biOasis Technologies Inc. (the “Company”) (TSX.V: BTI) announces that the “proof of concept” study documenting the companies innovative approach for the eradication of brain tumors and treating other diseases in the Central Nervous System (CNS) has been published by the prestigious journal PLoS ONE of the Public Library of Science. PloS ONE is an international, peer-reviewed, open-access, online publication. The paper entitled “ A Unique Carrier for the Delivery of Therapeutic Compounds Beyond the Blood-Brain Barrier” was published June 25 th and can be found at: http://www.plosone.org/doi/pone.0002469 . Professor Wilfred A. Jefferies, working at the Michael Smith Laboratories and the Biomedical Research Centre at The University of British Columbia, led the work.

The paper is a culmination of over 10 years of research by Professor Jefferies, his research group and collaborators studying the human protein p97, also termed melanotransferrin, an iron-transporting molecule that exhibits unique biochemical properties. Jefferies and his group at the University of British Columbia, had previously established the role of p97 as an iron transporter in the brain and this led to the discovery that p97 could effectively transverse the Blood Brain Barrier (BBB). Most therapeutic agents are blocked from entering the brain by the BBB that hampers the free distribution of drugs into the CNS. However, Professor Jefferies, who was recently appointed as Chairman of biOasis Technologies Inc's Scientific Advisory Board, hypothesized that p97 may be exploited to carry therapeutic agents across the BBB to the brain. The PloS ONE manuscript states “ This study provides the initial proof of concept for p97 as a carrier capable of shuttling therapeutic levels of drugs from the blood to the brain for the treatment of neurological disorders, including classes of resident and metastatic brain tumors. It may be prudent, therefore, to consider implementation of this novel delivery platform in various clinical settings for therapeutic intervention in acute and chronic neurological diseases.”

“This study demonstrates the utility of p97 as a shuttling molecule for the delivery of therapeutic agents such as anti-cancer drugs such as Adriamycin 1 & Paclitaxel through the BBB to tumors in the brain. We envisage p97's use as a new platform drug delivery system for the treatment of lysosomal storage disorders such as Gaucher's and Tai-Sachs diseases as well as neurodegenerative diseases such as Alzheimers's, Parkinson's and Huntington's. Based on our secured dominant, exclusive and unique intellectual property position in this area, biOasis is creating a second division within the company to advance the therapeutic applications of the “p97 drug delivery system”. We anticipate partnering with pharmaceutical companies that are developing therapeutics for neurological diseases.